Insider Selling: Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Sells 27,199 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the sale, the executive vice president now owns 488,054 shares in the company, valued at $868,736.12. This represents a 5.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Allogene Therapeutics Price Performance

Shares of ALLO opened at $1.88 on Friday. The business’s 50 day simple moving average is $2.12 and its 200-day simple moving average is $2.51. Allogene Therapeutics, Inc. has a one year low of $1.78 and a one year high of $5.78. The company has a market capitalization of $394.18 million, a P/E ratio of -1.21 and a beta of 0.86.

Hedge Funds Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ALLO. Federated Hermes Inc. bought a new position in shares of Allogene Therapeutics in the second quarter valued at about $29,000. Private Advisor Group LLC acquired a new stake in Allogene Therapeutics in the 3rd quarter valued at about $34,000. Algert Global LLC bought a new position in shares of Allogene Therapeutics in the second quarter worth about $35,000. MML Investors Services LLC bought a new position in shares of Allogene Therapeutics in the third quarter worth about $56,000. Finally, AQR Capital Management LLC acquired a new position in shares of Allogene Therapeutics during the second quarter worth approximately $64,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ALLO. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a report on Friday, November 8th. Piper Sandler decreased their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, William Blair reissued an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).